Robust SARS-CoV- 2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

E Zhang; THO Nguyen; LF Allen; L Kedzierski; LC Rowntree; SY Chang; W Zhang; JR Habel; IJ Foo; T Menon; J Mitchell; RW Leong; K Bond; DA Williamson; K Kedzierska; B Christensen

Journal article

Robust SARS-CoV- 2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

E Zhang, THO Nguyen, LF Allen, L Kedzierski, LC Rowntree, SY Chang, W Zhang, JR Habel, IJ Foo, T Menon, J Mitchell, RW Leong, K Bond, DA Williamson, K Kedzierska, B Christensen

Gut | Published : 2023

DOI: 10.1136/gutjnl-2022-329136

University of Melbourne Researchers

Oanh Nguyen Author

Lukasz Kedzierski Author

Louise Rowntree Author

WuJi Zhang Author

Related Projects (2)

Molecular Clamp Stabilized Spike Vaccine for Rapid Response

APPLYING PATHOGEN GENOMICS TO THE PREVENTION AND CONTROL OF ANTIMICROBIAL RESISTANCE

Antimicrobial resistance (AMR) is a huge threat to public health, both in Australia and globally. In some instances, having an AMR infection..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This work was supported by the GESA Rose Amarant Grant to EZ, Eric Charles Smith Grant to BC, NHMRC Leadership Investigator Grant to KK (#1173871), NHMRC Emerging Leadership Level 1 Investigator Grant to THON (#1194036), NHMRC Emerging Leadership Level 2 Investigator Grant to DAW (#1174555), Research Grants Council of the Hong Kong Special Administrative Region, China (#T11-712/19-Nn) to KK, MRFF Award (#2016062) to KK, THON and LCR, MRFF Award (#1202445) to KK, MRFF Award (#2005544) to KK.